- Home
- GDTC vs DYAI Comparison
GDTC vs DYAI Comparison
Compare GDTC & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- DYAI
- Stock Information
- Founded
- GDTC 2018
- DYAI 1979
- Country
- GDTC Singapore
- DYAI United States
- Employees
- GDTC N/A
- DYAI N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDTC Health Care
- DYAI Health Care
- Exchange
- GDTC Nasdaq
- DYAI Nasdaq
- Market Cap
- GDTC 28.0M
- DYAI 28.3M
- IPO Year
- GDTC 2023
- DYAI 2004
- Fundamental
- Price
- GDTC $1.86
- DYAI $1.10
- Analyst Decision
- GDTC Buy
- DYAI Strong Buy
- Analyst Count
- GDTC 1
- DYAI 1
- Target Price
- GDTC $5.00
- DYAI $6.00
- AVG Volume (30 Days)
- GDTC 10.3K
- DYAI 73.8K
- Earning Date
- GDTC 01-01-0001
- DYAI 08-12-2025
- Dividend Yield
- GDTC N/A
- DYAI N/A
- EPS Growth
- GDTC N/A
- DYAI N/A
- EPS
- GDTC N/A
- DYAI N/A
- Revenue
- GDTC $368,838.00
- DYAI $3,554,344.00
- Revenue This Year
- GDTC $5.37
- DYAI $22.56
- Revenue Next Year
- GDTC N/A
- DYAI $30.95
- P/E Ratio
- GDTC N/A
- DYAI N/A
- Revenue Growth
- GDTC N/A
- DYAI 57.59
- 52 Week Low
- GDTC $1.20
- DYAI $0.91
- 52 Week High
- GDTC $4.05
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- GDTC 41.07
- DYAI 53.81
- Support Level
- GDTC $1.96
- DYAI $0.91
- Resistance Level
- GDTC $2.26
- DYAI $1.03
- Average True Range (ATR)
- GDTC 0.10
- DYAI 0.05
- MACD
- GDTC -0.02
- DYAI 0.01
- Stochastic Oscillator
- GDTC 17.95
- DYAI 62.07
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.